Onco-Innovations Launches AI-Oncology Consortium

Onco-Innovations Limited's subsidiary, Inka Health, is set to launch a global consortium to advance AI in oncology. Named Predicting Oncology Outcomes using Multimodal AI (PROmAI), this initiative aims to unite pharmaceutical companies, academic institutions, and data science experts. Together, they will focus on improving predictive modeling in cancer research.

The PROmAI Consortium plans to develop next-gen AI approaches integrating diverse data sources. By targeting enhanced predictive accuracy and model relevance, the consortium seeks to overcome traditional limitations in oncology research.

This collaborative effort aims to foster personalized, cost-effective cancer care and set standards for AI transparency and trust in medical research. Discussions with prospective founding members are ongoing, with further announcements anticipated as partnerships are confirmed.